Výsledky vyhledávání

Efficacy and Safety of Etanercept Biosimilars Compared With the Originator for Treatment of Juvenile Arthritis: A Prospective Observational Study

Autor: Daniel Windschall, A. Hospach, J Michael Ruehlmann, Gerd Horneff, Ariane Klein, S. Mrusek, Franz Thiele

Publikováno v: ACR Open Rheumatology, Vol 3, Iss 11, Pp 779-787 (2021)
ACR Open Rheumatology

Objective Analysis of etanercept biosimilars in pediatric patients with juvenile idiopathic arthritis (JIA) in comparison with the etanercept originator in terms of efficacy and safety. Methods Patients diagnosed with JIA who started treatment with e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fea92fdb54e71e39f9085d501d5fccfe
https://doi.org/10.1002/acr2.11325

Zobrazit plný text záznamu

Highly efficient, low-temperature hydrogen release from perhydro-benzyltoluene using reactive distillation

Autor: Peter Wasserscheid, S. Mrusek, M. Geißelbrecht, Andreas Bösmann, Patrick Preuster, Karsten Müller

Publikováno v: Energy & Environmental Science. 13:3119-3128

The need to supply significant amounts of heat at the high temperature level required thermodynamically for cycloalkane dehydrogenation has so far been seen as the main hurdle to bring the otherwise highly attractive Liquid Organic Hydrogen Carrier (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bd7e218e0b8c9ea2373c6dcadc71fc70
https://doi.org/10.1039/d0ee01155j

Zobrazit plný text záznamu

POS0170 EXPERIENCES WITH COVID-19 INFECTIONS IN GERMAN PEDIATRIC RHEUMATOLOGY CENTERS

Autor: G. Horneff, F. Dressler, D. Windschall, S. Mrusek, T. Hospach, A. Kühn, M. Haller, P. Von Bismarck, W. Emminger, P. Ruehmer, M. Hufnagel, A. Klein

Publikováno v: Annals of the Rheumatic Diseases. 81:314-315

BackgroundAlthough the risk for severe COVID-19 progression in children is low, this may be aggravated by the underlying disease and/or immunosuppressive drugs.ObjectivesWe analyzed clinical data of COVID-19 cases among paediatric patients with rheum

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::583ea7656604fdf00a3c1adb7f5d6bbc
https://doi.org/10.1136/annrheumdis-2022-eular.1881

Zobrazit plný text záznamu

POS0171 A STANDARDIZED ASSESSMENT OF TREATMENT AND OUTCOME OF NEWLY DIAGNOSED PATIENTS WITH JIA WITHIN THE PROKIND PROJECT – PATHWAYS FOR POLYARTICULAR JIA

Publikováno v: Annals of the Rheumatic Diseases. 81:315.2-315

BackgroundThe ProKind Commission of the Society for Paediatric and Adolescent Rheumatology (GKJR) has developed evidence- and consensus-based protocols for the diagnosis and therapy of children and adolescents with defined rheumatic diseases (e.g., [

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4e44a42babcd6f174e77da9817c719cc
https://doi.org/10.1136/annrheumdis-2022-eular.2008

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

POS0075 SAFETY AND EFFICACY OF GOLIMUMAB FOR THE TREATMENT OF POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS - AN UPDATE FROM THE BIKER REGISTRY

Publikováno v: Annals of the Rheumatic Diseases. 80:244-245

Background:Golimumab (GOL) is approved for treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years and older. Data on long-term safety of GOL in this indication are limited.Objectives:To assess long-term safety and efficac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f020422d1bea3757b54ba27addd053b1
https://doi.org/10.1136/annrheumdis-2021-eular.2145

Zobrazit plný text záznamu

Rezidivierende Monarthritiden kleiner Gelenke: atypisches Leitsymptom eines spät erkannten familiären Mittelmeerfiebers

Autor: G. Ganser, S. Mrusek

Publikováno v: Arthritis und Rheuma. 37:142-146

Rezidivierende Monarthritiden kleiner Gelenke: atypisches Leitsymptom eines spat erkannten familiaren Mittelmeerfiebers

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5c69f52d9c9c53df85dba193d6cc428e
https://doi.org/10.1055/s-0037-1618411

Zobrazit plný text záznamu

THU0518 EFFICACY AND SAFETY OF ETANERCEPT IN JUVENILE IDIOPATHIC ARTHRITIS – 18 YEAR EXPERIENCE USING DATA OF THE BIKER REGISTRY

Autor: S. Mrusek, Ivan Foeldvari, Gerd Ganser, Kirsten Minden, Toni Hospach, Frank Dressler, Michael Rühlmann, Boris Huegle, Andreas Urban, Frank Weller-Heinemann, Jasmin B Kuemmerle-Deschner, Gerd Horneff, Ariane Klein, Ralf Trauzeddel

Publikováno v: Poster Presentations.

Background Since 2000, Etanercept is approved for polyarticular juvenile idiopathic arthritis (JIA). Subsequently, approval has been extended to additional JIA categories. Objectives To describe efficacy and safety of Etanercept in clinical practice

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::045ae2deae39685c217e2f2c125cab87
https://doi.org/10.1136/annrheumdis-2019-eular.1568

Zobrazit plný text záznamu

OP0163 COMPARATIVE ANALYSIS OF ETANERCEPT BIOSIMILAR AND ORIGINATOR USE IN CLINICAL PRACTICE: DATA FROM THE GERMAN BIKER-REGISTRY

Autor: S. Mrusek, Ariane Klein, D. Windschall, G. Horneff, Michael Rühlmann, Toni Hospach

Publikováno v: Annals of the Rheumatic Diseases. 80:98.1-98

Background:In 2017, 2 Etanercept biosimilars became approved. Comparative studies performed in adult patients with rheumatoid arthritis, ankylosing spondylitis or psoriasis by extrapolation led to approval for juvenile idiopathic arthritis (JIA).Obje

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3b077e79f1cf413ce6335bf48e60e0b5
https://doi.org/10.1136/annrheumdis-2021-eular.1003

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání